Intestinal Research

CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial

Tadakazu Hisamatsu, Reiko Kunisaki, Shiro Nakamura, Tomoyuki Tsujikawa, Fumihito Hirai, Hiroshi Nakase, Kenji Watanabe, Kaoru Yokoyama, Masakazu Nagahori, Takanori Kanai, Makoto Naganuma, Hirofumi Michimae, Akira Andoh, Akihiro Yamada, Tadashi Yokoyama, Noriko Kamata, Shinji Tanaka, Yasuo Suzuki, Toshifumi Hibi, Mamoru Watanabe,

Intest Res. 2018;16(3):494-498. Published online July 27, 2018
DOI: https://doi.org/10.5217/ir.2018.16.3.494

Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial

Intestinal Research. 2018;16(3):494

Link1 Link2 Link3

Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn’s disease: a cost-effectiveness analysis

G. G. KAPLAN, C. HUR, J. KORZENIK, B. E. SANDS

Alimentary Pharmacology & Therapeutics. 2007;26(11-12):1509-1520

Link1 Link2

P440 Loss of response and dose escalation of infliximab and adalimumab in Ulcerative Colitis patients: A Systematic Review and Meta-analysis

E Savelkoul, P Thomas, L Derikx, N Den Broeder, T Römkens, F Hoentjen

Journal of Crohn's and Colitis. 2022;16(Supplement_1):i422-i423

Link1

Link2

W1335 Previous Non-Response to Infliximab Predicts Early Dose-Escalation in Adalimumab Treated Crohn's Disease Patients

Evelien Bultman, Rachel L. West, Astrid van Liere-Baron, Ernst J. Kuipers, Zuzana Zelinkova, Janneke V. Woude

Gastroenterology. 2010;138(5):S-701-S-702

Link1 Link2

Sa1974 Rational Infliximab De-Escalation in Crohn's Patients in Remission Using Infliximab Levels

Jessica R. Allegretti, Madeline Carrellas, Matthew Hamilton, Sonia Friedman, Joshua R. Korzenik

Gastroenterology. 2016;150(4):S421

Link1 Link2

Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review

Javier P Gisbert, Julián Panés

The American Journal of Gastroenterology. 2009;104(3):760-767

Link1

Link2 Link3

W1270 Discriminating Between Response Types in Infliximab-Treated Patients With Crohn's Disease: Sensitivity and Specificity of Combined Assessment of Infliximab Trough Levels and Anti-Drug Antibodies

Casper Steenholdt, Ole O. Thomsen, Jorn Brynskov, Klaus Bendtzen, Mark A. Ainsworth

Gastroenterology. 2010;138(5):S-687-S-688

Link1 Link2

Su1225 Concomitant Elemental Diet Therapy Is Effective in Sustaining Infliximab Scheduled Maintenance Therapy in Patients With Crohn's Disease to Prevent Loss of Response

Noriko Kamata, Kenji Watanabe, Takuya Tsukahara, Yoshie Hagihara, Kenichi Morimoto, Atsushi Noguchi, Takako Miyazaki, Mitsue Sogawa, Hirokazu Yamagami, Tetsuya Tanigawa, Masatsugu Shiba, Toshio Watanabe, Kazunari Tominaga, Yasuhiro Fujiwara, Tetsuo Arakawa

Gastroenterology. 2013;144(5):S-433

Link1 Link2

Effect of antibodies to infliximab on infusion reaction and clinical response in patients with fistulizing Crohn's disease receiving maintenance treatment with infliximab

Carrie Wagner, Joyce Ford, Paul Marsters, Suzanne Travers, Weihang Bao, Sander J. Van Deveneter

Gastroenterology. 2003;124(4):A380

Link1 Link2

Sa2049 One Third of Patients Treated With Adalimumab or Infliximab for Crohn's Disease or Ulcerative Colitis Permanently Dose-Escalate Due to Loss of Response

Darryl K. Fedorak, Pam Osatiuk, Karen Wong, Karen I. Kroeker, Levinus A. Dieleman, Richard N. Fedorak

Gastroenterology. 2012;142(5):S-389

Link1 Link2